Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 104,100 shares, a growth of 42.4% from the February 28th total of 73,100 shares. Based on an average trading volume of 75,500 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.6% of the company’s shares are short sold.

Talphera Price Performance

TLPH opened at $0.54 on Tuesday. The firm has a market capitalization of $9.11 million, a PE ratio of -0.76 and a beta of 0.20. Talphera has a fifty-two week low of $0.45 and a fifty-two week high of $1.27. The company’s 50-day moving average is $0.61 and its 200 day moving average is $0.71.

Talphera (NASDAQ:TLPH) last announced its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.14. As a group, analysts expect that Talphera will post -0.64 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Rodman & Renshaw initiated coverage on Talphera in a report on Tuesday, January 28th. They issued a “buy” rating and a $4.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Talphera in a research note on Tuesday. Finally, RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a report on Tuesday, January 28th.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.